AIMS: The cellular response to hypoxia includes the hypoxia inducible factor (HIF)-induced transcription of genes involved in diverse processes such as glycolysis, angiogenesis and the growth of experimental tumours. Regulation of the level of hypoxia inducible factors 1alpha and 2alpha (HIF-1alpha and HIF-2alpha) is a primary determinant of HIF activity. Recent biochemical and candidate gene approach studies have led to the discovery of three HIF-regulatory prolyl hydroxylases, PHD-1, -2 and -3 and an asparaginyl hydroxylase, also known as FIH (factor inhibiting HIF). In this study, we raised and characterized monoclonal antibodies against PHD-1, PHD-2, PHD-3 and FIH. METHODS AND RESULTS: Immunohistochemistry of normal tissues with these monoclonal antibodies demonstrated a wide distribution in epithelial cells, stromal cells and leucocytes, with cytoplasmic staining predominating over nuclear staining. A preliminary study of tumours showed variable staining in tumour, stromal and inflammatory cells. While all tumour types showed some positive staining with each antibody, the overall pattern suggested a slight decrease in the amount of staining seen with PHD-1, -2 and -3 and an increase in FIH staining in neoplasia compared with corresponding normal tissues. CONCLUSIONS: These monoclonal antibodies will allow further larger scale studies to determine the significance of PHD and FIH expression in neoplasia.
AIMS: The cellular response to hypoxia includes the hypoxia inducible factor (HIF)-induced transcription of genes involved in diverse processes such as glycolysis, angiogenesis and the growth of experimental tumours. Regulation of the level of hypoxia inducible factors 1alpha and 2alpha (HIF-1alpha and HIF-2alpha) is a primary determinant of HIF activity. Recent biochemical and candidate gene approach studies have led to the discovery of three HIF-regulatory prolyl hydroxylases, PHD-1, -2 and -3 and an asparaginyl hydroxylase, also known as FIH (factor inhibiting HIF). In this study, we raised and characterized monoclonal antibodies against PHD-1, PHD-2, PHD-3 and FIH. METHODS AND RESULTS: Immunohistochemistry of normal tissues with these monoclonal antibodies demonstrated a wide distribution in epithelial cells, stromal cells and leucocytes, with cytoplasmic staining predominating over nuclear staining. A preliminary study of tumours showed variable staining in tumour, stromal and inflammatory cells. While all tumour types showed some positive staining with each antibody, the overall pattern suggested a slight decrease in the amount of staining seen with PHD-1, -2 and -3 and an increase in FIH staining in neoplasia compared with corresponding normal tissues. CONCLUSIONS: These monoclonal antibodies will allow further larger scale studies to determine the significance of PHD and FIH expression in neoplasia.
Authors: Jui-Han Huang; Frank S Lee; Theresa L Pasha; Mary D Sammel; Giorgos Karakousis; George Xu; Douglas Fraker; Paul J Zhang Journal: Cancer Biol Ther Date: 2009-12-22 Impact factor: 4.742
Authors: Andreas Robinson; Simon Keely; Jörn Karhausen; Mark E Gerich; Glenn T Furuta; Sean P Colgan Journal: Gastroenterology Date: 2008-01 Impact factor: 22.682
Authors: Valerie Hower; Pedro Mendes; Frank M Torti; Reinhard Laubenbacher; Steven Akman; Vladmir Shulaev; Suzy V Torti Journal: Mol Biosyst Date: 2009-03-06
Authors: Johannes Schödel; Bernd Klanke; Alexander Weidemann; Björn Buchholz; Wanja Bernhardt; Marko Bertog; Kerstin Amann; Christoph Korbmacher; Michael Wiesener; Christina Warnecke; Armin Kurtz; Kai-Uwe Eckardt; Carsten Willam Journal: Am J Pathol Date: 2009-04-06 Impact factor: 4.307
Authors: A M Jubb; H Turley; H C Moeller; G Steers; C Han; J-L Li; R Leek; E Y Tan; B Singh; N J Mortensen; I Noguera-Troise; F Pezzella; K C Gatter; G Thurston; S B Fox; A L Harris Journal: Br J Cancer Date: 2009-10-20 Impact factor: 7.640